

SCOLR Pharma, Inc.  
Form 8-K  
June 28, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant To Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report: June 20, 2012**

**(Date of earliest event reported)**

**SCOLR Pharma, Inc.**

**(Exact name of registrant as specified in its charter)**

Edgar Filing: SCOLR Pharma, Inc. - Form 8-K

(State or other jurisdiction  
of incorporation)

(Commission

(I.R.S. Employer

File Number)

Identification No.)

**13400 NE 20<sup>th</sup> Street, Suite 44**

**Bellevue, Washington 98005**

(Address of principal executive offices and zip code)

**(425) 368-1050**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**SCOLR PHARMA, INC.**

**FORM 8-K**

**Item 2.02. Results of Operations and Financial Conditions.**

On June 20, 2012, SCOLR Pharma, Inc. announced its unaudited net sales of its nutritional products for the fourth quarter and year ended December 31, 2011 and the first quarter ended March 31, 2012. A copy of the press release containing this information is attached to this current report as Exhibit 99.1.

The information contained herein, including the exhibit attached hereto, is being furnished and shall not be deemed filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained herein and in the accompanying exhibit shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filings.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
99.1	SCOLR Pharma, Inc. press release, dated June 20, 2012.

**Signature**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SCOLR Pharma, Inc.  
(Registrant)

June 28, 2012  
(Date)

By: */s/* **STEPHEN J. TURNER**  
**Stephen J. Turner**  
**President and Chief Executive Officer**